



IncyteCARES for Jakafi Program Enrollment Form

(Page 1 of 4)

Please legibly complete all fields not marked optional, for timely processing. Fax completed form to 1-855-525-7207. We will contact you within 2 business days. For questions, call 1-855-452-5234.

For details about all program services your patient can receive upon enrollment, see HCP.IncyteCARES.com/Jakafi.

□ Check here to request only a Benefits Investigation for your patient.

PATIENT INFORMATION - -----

Full Name	Date of Birth//
Home Address	
City	State ZIP
Medicare ID (Optional) Email (Opt	ional)
Phone Number Alternate Phone N	umber (Optional)
Best Time to Call (Optional)	vening
Primary Language (Optional) 🗌 English 🗌 Spanish 🗌 Oth	er
Is patient a resident of the United States or Puerto Rico? $\hfill United States or Puerto Rico?$	🗌 No
ALTERNATE CONTACT (Optional)	
Full Name Relationsh	ip Phone Number
FINANCIAL INFORMATION (Optional) —Required only to apply for the See HCP.IncyteCARES.com/Jakafi for details.	e Patient Assistance Program.
Current Annual Household Income	Number of People in Household
INSURANCE INFORMATION	
Primary Prescription Insurer	Phone
Policy ID Number Group	Number
If patient is the policy subscriber, check here and skip fields below.	
Subscriber Name	Subscriber Date of Birth//
Secondary Prescription Insurer (Optional)	Phone
Policy ID Number Group	Number
If patient is not the policy subscriber, check here and complete field	s below. 🗌
Subscriber Name	Subscriber Date of Birth//

Fax completed form to 1-855-525-7207. Need help? Call us at 1-855-452-5234.

For complete program details, visit HCP.IncyteCARES.com/Jakafi.

IncyteCARES

PRESCRIBER DECLARATION

I verify that the patient and prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed Jakafi based on my professional judgment of medical necessity.

I represent and warrant that I have my patient's authorization on file to (i) disclose his/her health information and to transfer such information to Incyte and its agents to use and disclose as necessary to provide reimbursement services and (ii) to forward this prescription to a dispensing pharmacy on behalf of my patient. I appoint IncyteCARES solely to convey on my behalf, to the pharmacy chosen by or for the patient, the prescription described herein.

I authorize IncyteCARES to perform a preliminary assessment of insurance verification for the patient, and I further authorize and request that the program provide to me any and all information necessary for completing a Letter of Medical Necessity as may be required as a result of such insurance verification assessment.

☐ I have read and agree to the declaration above.

Date / /

Prescriber Name _____

PRESCRIPTION FOR JAKAFI

Use this section to write your patient's prescription. A separate prescription form is not needed, unless required by state law.	Date / /			
Patient Name	Date of Birth//			
Medication Name: Jakafi® (ruxolitinib) Dosage: 🗌 5 mg 🗌 10 mg	🗌 15 mg 🔲 20 mg 🗌 25 mg			
Directions				
Concurrent Medications 🛛 None				
Allergies 🗌 No Allergies				
Days Supply: Refill(s) DEA Number				
Ship medication to: \Box Patient's Home \Box Doctor's Office				
Preferred Specialty Pharmacy (Optional)				
Prescriber Signature	Date//			
PRESCRIBER INFORMATION				
Prescriber Full Name				
Collaborative Physician Name (If applicable)				
State License Number Payer-Specific ID	Payer-Specific ID Number			
Tax ID Number NPI Number				
Site/Facility Name				
Street Address City	State ZIP			
Office Contact Name Email (Optional)				
Phone Number Fax Number				
Fax completed form to 1-855-525-7207 . Need help? Call us at 1-855-452-5234. For complete program details, visit HCP.IncyteCARES.com/Jakafi .				



CLINICAL INFORMATION

Indication for which you are prescribing Jakafi® (ruxolitinib) for this patient:

- □ Intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF in adults
- Polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea
- Steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older
- Chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older
- Other (include description and diagnosis code) _

Treatment status:	🗌 New to Jakafi	🗌 Currently on Jakafi	🗌 Restarting Jakafi
-------------------	-----------------	-----------------------	---------------------

PATIENT AUTHORIZATION

All fields are required unless noted.

I authorize my healthcare providers (eg, physicians, pharmacies) and my insurance company to disclose personal health information about me, including information related to my medical condition and treatment, my health insurance coverage, and my address, email address, and telephone number (collectively, my "PHI") to Incyte, its agents, and the IncyteCARES Program (collectively, "Incyte") so that Incyte may use the information for purposes of: (i) assisting in my enrollment in IncyteCARES; (ii) assessing my eligibility for copay assistance or free drug or referring me to other programs or sources of funding and financial support; (iii) coordinating delivery of Jakafi[®] (ruxolitinib) to me or my healthcare provider; (iv) providing education, information on Incyte products and services, and ongoing support services to me related to Jakafi; (v) gathering feedback on my therapy and/or disease state; (vi) contacting me by mail, email, phone, or fax for any of the above purposes; and (vii) creating information that does not identify me personally for use for other purposes related to Jakafi. I understand that my pharmacy providers may receive remuneration for making such disclosures. I also authorize my healthcare providers and my insurance company to use my PHI to communicate with me about Incyte products and services and I understand that they may receive remuneration for making such communications. I understand that, once disclosed pursuant to

Continued on next page

Fax completed form to 1-855-525-7207. Need help? Call us at 1-855-452-5234. For complete program details, visit **HCP.IncyteCARES.com/Jakafi**.

IncyteCARE

IncyteCARES for Jakafi Program Enrollment Form

(Page 4 of 4)

this authorization, my PHI may no longer be protected under federal or state law and could be disclosed by Incyte to others, but I understand that Incyte will make reasonable efforts to keep it private and to disclose it only for the purposes set forth in this authorization.

I understand that I do not have to sign this authorization to obtain healthcare treatment or benefits; however, in order to receive the services and communications described above, I must sign the authorization. I understand that I may cancel my authorization at any time by contacting IncyteCARES at 1-855-452-5234 or by mail at PO Box 221798, Charlotte, NC 28222-1798. My cancellation of this authorization will be effective when my healthcare providers and insurance companies are notified of its receipt by Incyte, but will not apply to PHI already used or disclosed in reliance upon this authorization.

I understand that I have a right to receive a copy of this authorization. This authorization expires one year after the date below unless I cancel it before then. To review Incyte's Privacy Policy, please visit **https://incyte.com/privacy-policy.**

□ For patients eligible for IncyteCARES education and support program (which includes occasional emails and outbound calls): I agree to be contacted by Incyte, its agents, and the IncyteCARES program representatives about information on Incyte products and services at the email address and phone number(s) provided in my enrollment form. I can cancel this authorization at any time by emailing privacy@incyte.com.

Patient's Full Name						
Signature	Date	/	/			
Patient's Legal Representative (Optional)						
Signature	Date	/	/			
Relationship with patient						
Fax completed form to 1-855-525-7207 . Need help? Call us at 1-855-452-5234.						

